Plasma exchange was undertaken in five patients with homozygous familial hypercholesterolaemia at intervals of two weeks for a mean of 8-4 years. These patients had survived an average of 5 5 years longer than their five respective homozygous siblings (p = 0.03), each of whom must have had a matching genetic defect but who died untreated. The 37% decrease in peak serum cholesterol concentrations maintained by plasma exchange presumably reduced progression of atherosclerosis in the treated patients and thus lessened their risk of premature death.
Introduction
The use of plasma exchange to treat homozygous familial hypercholesterolaemia was first introduced 10 years ago. ' Familial hypercholesterolaemia can be caused by any one of the seven described mutations of the gene for the low density lipoprotein receptor2 that has recently been cloned. 3 Inheritance of identical or dissimilar mutant alleles from each parent gives rise to the homozygous form of the disease, which is characterised by a considerable increase in low density lipoprotein cholesterol concentration from birth, appearance of cutaneotendinous xanthomas and onset of aortocoronary atherosclerosis in childhood, and a liability to sudden death in early adult life. 4 Familial hypercholesterolaemia is notoriously resistant to treatment with diet and drugs, although receptor defective homo-zygotes, who have detectable low density lipoprotein receptor activities, respond better than receptor negative homozygotes, in whom such activities are absent.4" These differences reflect the nature of the underlying mutation and result in considerable variability between homozygotes with respect to the speed of onset of cardiovascular complications6 and age at death.4 This paper reports the beneficial effects of plasma exchange on the survival of five homozygotes treated after 1975, each of whom had a homozygous sibling, with a presumed identical defect of low density lipoprotein receptor, who died without undergoing this treatment.
Subjects and methods
All five patients have been described in detail previously.7`Two ( Table 1 shows the low density lipoprotein receptor state and basal serum lipid concentrations in the five homozygotes who underwent plasma exchange. One patient (case 5) was receptor negative, the four others receptor defective. All had severe hypercholesterolaemia, which, in the presence of normal triglyceride and subnormal high density lipoprotein cholesterol concentrations, can be calculated as being due to roughly fourfold increase in low density lipoprotein cholesterol concentrations. 12 Table II shows details of the age and sex of these patients and their homozygous siblings, together with the duration and cholesterol lowering effect of plasma exchange. This procedure has been performed for the past nine years in four patients and for six years in the remaining patient (case 3). Conversion: SI to traditional units-Cholesterol: 1 mmoll 38-6 mg/100 ml.
Reduction in serum cholesterol concentrations ranged from 3441%, being least in the receptor negative patient (case 5). Table II also shows the age of death of the untreated homozygotes and age at which plasma exchange was begun in their siblings. Three sibling pairs were all male, two were mixed. All but one of the treated patients are still alive, and he (case 1) died postoperatively, whereas all their untreated homozygous siblings are deceased. In each instance death of siblings was sudden and due to atherosclerosis, as described previously.89 All but one of the treated patients survived longer than their respective siblings, the mean difference in life span being 5 5 years. Application of the paired log rank test shows that this difference is significant (one tailed, p = 003).
Discussion
Plasma exchange has been used to treat homozygous familial hypercholesterolaemia in several centres during the past 10 years.' 914-16 The safety and beneficial effects of this procedure in 13 such patients were reviewed four years ago,' and thereafter further reports have appeared.'8 20 Regression of cutaneous and tendinous xanthomas is well documented, and there is evidence that this is usually,'2' but not always,22 accompanied by a reduced rate of progression of aortocoronary lesions. Serum cholesterol concentrations measured immediately before plasma exchange, when they are at their highest, are 40% lower than with conventional treatment, which represents a 50% reduction in the mean plasma concentration sibling is bound to have inherited the same pair of mutant alleles from their heterozygous parents. Measurement of low density lipoprotein receptor activity in siblings confirms the validity of this assumption.' Differences of sex seem less important in determining the onset of cardiovascular complications in homozygotes25 than in heterozygotes,26 28 and receptor state seems to be the overriding factor. High density lipoprotein cholesterol concentrations were subnormal in all five homozygotes before plasma exchange was initiated, which is common.4 Four of the five patients underwent surgical procedures, but probably none of these was operative for long enough to have influenced prognosis.
Although the numbers were small, the duration of treatment was sufficiently long to show that plasma exchange signficantly improves life expectancy in homozygous familial hypercholesterolaemia. The beneficial effect of this procedure may have been enhanced by concomitant administration of lipid lowering drugs, notably nicotinic acid and more recently mevinolin. 29 The latter in a dose of 80 mg/day resulted in a further 11-5% reduction in serum cholesterol concentration before exchange compared with that in plasma exchange alone (unpublished data). The net result was a halving of low density lipoprotein cholesterol concentrations, which presumably was the chief reason for the clinical improvement and stabilisation of atherosclerotic lesions documented previously.7
Plasma exchange also reduces plasma fibrinogen concentrations, platelet counts, and high density lipoprotein cholesterol concentra-tions, but these all return to normal within a week, 30 We thank all our colleagues, both doctors and nurses, whose skill and stamina have enabled well over 1000 plasma exchanges to be undertaken over the past 10 years without mishap, Drs J Goldstein and M Brown for measuring the low density lipoprotein receptor state of fibroblasts from the three patients treated in Britain, and Dr R Peto and Mr D Robinson for undertaking the statistical analysis.
Introduction
It is not clear whether the al antitrypsin PiMZ heterozygous state predisposes to lung disease.`4 We report on a patient with the PiMZ phenotype who at the age of 36 had severe emphysema, evidence of hepatic cirrhosis, and complete heart block. Neither severe lung disease nor liver disease is a recognised feature of the PiMZ phenotype, and heart block has not previously been reported in association with partial a, antitrypsin deficiency.
